YCC Publications 2025

For 2024 publications go here.

•

Hunter CJ, Cheng W, Bewersdorf JP, Boddu P, Browning S, Halene S, Parker T, Huntington SF, Kothari S, Mendez L, Neparidze N, Sethi T, Barbarotta L, Podoltsev NA, Zeidan AM, Shallis RM. Feasibility, safety and outcomes of patients with newly diagnosed acute myeloid leukemia discharged 'early' after intensive induction. Leuk Lymphoma. 2025 Oct 29:1-12.

Tran TT, Sánchez-Zuno GA, Osmani L, Caulfield J, Valdez CN, Piecychna M, Leng L, Armstrong ME, Donnelly SC, Bifulco CB, Clister T, Kulkarni RP, Zhang L, Sznol M, Jilaveanu L, Kluger HM, Kang I, Bucala R. Improving immunotherapy responses by dual inhibition of macrophage migration inhibitory factor and PD-1. JCI Insight. 2025 Oct 22;10(20):e191539.

Schiff D, Ye X, Li J, Ellingson BM, Wen PY, Walbert T, Campian J, Burt Nabors L, Ozer BH, Desai A, Omuro A, Desideri S, Danda N, Grossman S, Bindra RS. Phase I/II and Window-of-Opportunity Study of Pamiparib and Metronomic Temozolomide for Recurrent IDH Mutant Gliomas. Neuro Oncol. 2025 Oct 16:noaf246.

Wang X, Lee DH, Yang SC, Li Y, Soulos PR, Gross CP, Wang SY, Chiang AC. Molecular Biomarker Testing Patterns and Turnaround Time in US Patients With Advanced Non-Small Cell Lung Cancer. J Natl Compr Canc Netw. 2025 Oct 10:1-7.

Butensky SD, Schultz KS, Godfrey EL, Kim J, Sanft T, Johnson CH, Leeds IL, Khan SA. Psychosocial Risk Factors and Perceived Well-Being in Survivors of Gastrointestinal Cancer. Psychooncology. 2025 Oct;34(10):e70302.

Westvold SJ, Long JB, Fan J, Kc M, Hyslop T, Conlin K, Jacobson S, Silber A, Wang SY, Leapman MS, Leeds I, Spees L, Wheeler SB, Gross CP, Oeffinger K, Dinan MA. Cardiovascular risk in long-term survivors of breast, prostate, colon, and rectal cancer. J Natl Cancer Inst. 2025 Oct 9:djaf243.

Cheung JF, Hunt BG, Wahed S, Cheng E, Connolly KA, Venkatesan S, Loza JL, Bansal I, Fagerberg E, Kessler EA, Riffard C, Buck J, Attanasio J, Borr ER, Wei W, William I, Fitzgerald B, Joshi NS. Distinct T cell functions enable efficient immunoediting and prevent tumor emergence of developing sarcomas. Cancer Cell. 2025 Oct 2:S1535-6108(25)00397-6.

Frey A, Clulo K, Fei Y, Dumit TC, Scallo F, Allen JW, Chang E, Perry CJ, Wirth LV, Jacobs D, Braun DA, Bosenberg MW, Tran TT, Clune J, Kluger HM, Olino K, Ishizuka JJ. Targeting an essential viral oncoprotein with an IL-7-enhanced mRNA vaccine induces durable immunity to Merkel cell carcinoma. Cell Rep. 2025 Oct 28;44(10):116359.

Meng Z, Gao X, Tang X, Fan J, Sheu WC, Tu Z, Yu J, Long G, Wang L, Liu R, Zhou J. Signal Transducer Nanoparticles Enable Siglec-10/G Blockade Immunotherapy for Breast Cancer Treatment. Adv Mater. 2025 Oct;37(39):e2502758.

Fereydooni S, Fereydooni S, Williams L, Verma A, Judson B. Association of Policy With Palliative Care Uptake in Patients With Head and Neck Cancer. Head Neck. 2025 Oct;47(10):2693-2701.

Ianniello Z, Lu H, Quijano E, Colón-Ríos DA, Rackear M, Bommireddy V, Ludwig DL, Shen Z, Glazer PM. Harnessing ExDNA for precision exatecan delivery in cancer: a novel antibody-drug conjugate approach. Mol Cancer. 2025 Oct 13;24(1):253.

Aung TN, Monkman J, Warrell J, Vathiotis I, Bates KM, Gavrielatou N, Trontzas IP, Tan CW, Fernandez AI, Moutafi M, O' Byrne K, Schalper KA, Syrigos K, Herbst RS, Kulasinghe A, Rimm DL. Spatial signatures for predicting immunotherapy outcomes using multi-omics in non-small cell lung cancer. Nat Genet. 2025 Oct;57(10):2482-2493.

Cortes J, Lipatov O, Im SA, Goncalves A, Lee KS, Schmid P, Tamura K, Testa L, Ohtani S, Harbeck N, Loi S, Salgado R, Karantza V, Mejia J, Cristescu R, Loboda A, Nebozhyn M, Jelinic P, Huang L, Winer EP. Association of potential biomarkers with clinical outcomes in metastatic triple-negative breast cancer treated with pembrolizumab or chemotherapy. NPJ Breast Cancer. 2025 Oct 2;11(1):109.

Bold KW, Kong G, Morean ME, Sharma A, Courtney W, Li W, Davis DR, Camenga D, Ouellette R, Krishnan-Sarin S. Understanding Reasons to Quit or Reduce Vaping and Associations With Quitting Outcomes Among High School Adolescents in Connecticut. J Adolesc Health. 2025 Oct;77(4):766-770.

Leader AE, Loeb S, Selvan P, Hunter A, Hartman R, Keith SW, and Giri VN. A Social Media Campaign and Web-Based Survey About Prostate Cancer Genetics: Mixed Methods Study. JMIR Cancer. 2025 Oct 14;11:e69787.

Zhang Y, Kesler SR, Dietrich J, Chao HH. Cancer-Related Cognitive Impairment: A Practical Guide for Oncologists. JCO Oncol Pract. 2025 Oct;21(10):1377-1381.

Sacher AG, Miller WH Jr, Patel MR, Paz-Ares L, Santoro A, Ahn MJ, Dziadziuszko R, Freres P, Luo J, Bowyer S, Desai J, Markman B, De Miguel M, Deva S, Falcon A, Alonso G, Guedes JD, Kim SH, Krebs MG, Laurie SA, Massarelli E, Medina L, Prenen H, Amatu A, Van Dongen M, Choi Y, Hou X, Qi T, Lin MT, Koli K, Mayo MC, Yau KK, Royer-Joo S, Chang J, Jun T, Dharia NV, Schutzman JL, Lorusso P; GO42144 Investigator Study group; GO42144 Investigator Study Group. Single-Agent Divarasib in Patients With KRAS G12C-Positive Non-Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study. J Clin Oncol. 2025 Oct 20;43(30):3249-3253.

Oladeru OT, Richman IB, Aminawung JA, Weinstein J, Puglisi LB, Mehta R, Lin HJ, Wang EA, Gross CP. Incarceration and Quality of Cancer Care. JAMA Netw Open. 2025 Oct 1;8(10):e2537400.

Ning X, Wang R, Ogilvie J, Dinauer C, Ma X, Deziel NC. Evaluation of disparities in the incidence, presentation, and treatment of pediatric differentiated thyroid cancer in the United States (2000-2022). PLoS One. 2025 Oct 16;20(10):e0333401.

Siddique S, Wang R, May FP, Baum LVM, Gross CP, Ma X. Changes in Colorectal Cancer Screening Modalities Among Insured Individuals. JAMA Netw Open. 2025 Oct 1;8(10):e2538578.

Kunst N, Long JB, Sprenkle PC, Kim IY, Saperstein L, Rabil M, Ghaffar U, Karnes RJ, Ma X, Gross CP, Wang SY, Leapman MS. Cost-Effectiveness and Evidence Gaps Surrounding PSMA-PET for Recurrent Prostate Cancer Evaluation. JAMA Netw Open. 2025 Oct 1;8(10):e2539250.

Osoliniec VE, Thomas MA, de Graaf RA, De Feyter HM. Oral intake of deuterated choline at clinical dose for metabolic imaging of brain tumors. Npj Imaging. 2025 Oct 24;3(1):54. doi: 10.1038/s44303-025-00113-y. PMID: 41136682; PMCID: PMC12552732.

Gisriel SD, Aakash F, Bennett JM, Hasserjian RP, Loghavi S, DeZern AE, Santini V, Savona MR, Brunner AM, Buckstein R, Wei AH, Della Porta MG, Komrokji RS, Borate UM, Sekeres MA, Platzbecker U, Fenaux P, Roboz GJ, van de Loosdrecht A, Zeidan AM, Xu ML. Standardization of Bone Marrow Reporting for Myelodysplastic Syndromes/Neoplasms on Behalf of the International Consortium for Myelodysplastic Syndromes/Neoplasms. Arch Pathol Lab Med. 2025 Oct 1;149(10):968-976.

Liu M, Townsend JP. KRAS G12C-associated immunotherapy benefit in NSCLC is substantially mediated by tobacco-induced tumor mutation burden, not allele-specific effects. Lung Cancer. 2025 Sep 16;209:108749.

Richman IB, Lindsay ME, Long JB, Epstein E, Sheffrin M, Berger ER. Diagnostic yield of surveillance mammography among older women. J Natl Cancer Inst. 2025 Sep 26:djaf270. doi: 10.1093/jnci/djaf270.

Richman I, Long JB, Lindsay ME, Fendrick AM, Kyanko K, Gross CP. Changes in Use, Cost, and Value of Breast Cancer Screening Among Older Women in the US. J Gen Intern Med. 2025 Sep 23.

Dinan MA, Stratton KL, Leisenring WM, Yasui Y, Chow EJ, Tonorezos ES, Moskowitz CS, Yeh JM, Noyd D, Armstrong GT, Oeffinger KC. Treatment exposure-based risk-stratification for care of survivors of childhood cancer: a report from the childhood cancer survivor study. J Natl Cancer Inst. 2025 Sep 14:djaf268.

Sivanesan N, Diaz GM, Strachan S, Kandala K, Zhao X, Tan WS, Leapman MS, Sprenkle PC. MRI-fusion biopsy era: the role of perineural invasion in low-risk prostate cancer. Curr Probl Cancer. 2025 Sep 13;59:101251.

Aizenbud L, Savion Gaiger N, Perdigoto AL, Mann JE, Torres MC, Boland GM, Lawless AR, Silverman S, Schoenfeld DA, Destina JI, Hasson N, Tran T, Hurwitz M, Austin MR, Sullivan RJ, Herold KC, Kluger HM. Factors that increase class I MHC expression may contribute to the development of immune checkpoint inhibitor-induced diabetes. J Immunother Cancer. 2025 Sep 10;13(9):e012358.

Joldoshova A, Khandakar B, Lee H, Lam R, Jain D. Biliary pseudo tumor associated with hepatic atrophy. Hum Pathol. 2025 Sep;163:105879.

Zhan H, Chan NNN, Khaimova R, Aung TN, Gaule P, Robbins CJ, Rimm DL. Quantitative assessment of HER2 expression in invasive ductal carcinoma and co-existing DCIS. Breast Cancer Res Treat. 2025 Sep;213(2):273-279.

Herbst RS, Cho BC, Zhou C, Burotto M, Dols MC, Sendur MAN, Moiseyenko V, Casarini I, Nishio M, Hui R, Pons-Tostivint E, Dudnik J, Ahmed S, Okpara CE, Dutcus C, Yin L, Luo Y, Chirovsky D, Bhagwati N, Abreu DR. Lenvatinib Plus Pembrolizumab, Pemetrexed, and a Platinum as First-Line Therapy for Metastatic Nonsquamous NSCLC: Phase 3 LEAP-006 Study. J Thorac Oncol. 2025 Sep;20(9):1302-1314.

Demirkiran C, Bellone S, Ettorre VM, Mansolf M, Hartwich TMP, McNamara B, Greenman M, Yang-Hartwich Y, Ratner E, Santin NG, Sethi N, Palmieri L, Coma S, Pachter JA, Ottum S, Santin AD. Preclinical Efficacy of the Estrogen Receptor Degrader Fulvestrant in Combination with RAF/MEK Clamp Avutometinib and FAK Inhibitor in a Low-Grade Serous Ovarian Cancer Animal Model with Acquired Resistance to Chemotherapy and Aromatase Inhibitor. Int J Mol Sci. 2025 Sep 13;26(18):8924.

Sefik E, Philbrick W, Zhang F, Agrawal K, Van Lee B, Sam J, Karatepe K, Zheng Y, Liang K, Peng S, Mirza H, Rangavajhula A, Simon P, Arun N, Babu P, Eynon E, Chiorazzi M, Shan L, Halene S, Luo HR, Rongvaux A, Kluger Y, Flavell RA. Humanization of CD47 enables development of functional human neutrophils via postirradiation remodeling of the bone marrow. Proc Natl Acad Sci U S A. 2025 Sep 23;122(38):e2426546122.

Lu Y, Yurkevicz AM, Liu Y, Glazer PM. Hypoxia Induces Immunosuppression by Silencing STING in Cancer. Cancer Res. 2025 Sep 12:10.1158/0008-5472.CAN-24-2038.

Zhang JY, Rajendran BK, Desai SS, Gibson J, DiPalermo J, LoRusso P, Kong Y, Zhao H, Cecchini M, Schalper KA. High MGMT expression identifies aggressive colorectal cancer with distinct genomic features and immune evasion properties. J Immunother Cancer. 2025 Sep 10;13(9):e011653.

Santin NG, Sethi N, Bellone S, Demirkiran C, Ettorre VM, Greenman M, McNamara B, Buza N, Hartwich TMP, Palmieri L, Lorusso D, Santin AD. Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody-Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas. Cancer Res Commun. 2025 Sep 1;5(9):1611-1620.

Yu J, Tu Z, Fan J, Lei K, Meng Z, Chen B, Wang Z, Escobar W, Zhou J. Phosphatidylcholine-derived carriers facilitate brain tumor delivery and enhance glioblastoma therapy. J Control Release. 2025 Sep 10;385:113999.

Kidacki M, Cho C, Lopez-Giraldez F, Breidbart R, Jaiswal A, Lee M, Chowdhury S, Damsky W, Chen L, Vesely MD. Spatial Transcriptomics Reveals Differential Inflammatory Pathways in Discoid Lupus Erythematosus and Lichen Planus. J Invest Dermatol. 2025 Sep;145(9):2344-2348.e7.

Greenberg ABW, Valido K, Vesely M, Leventhal JS. The treatment of cutaneous immune-related adverse events from immune checkpoint inhibitors with biologic therapy: A single-institution retrospective study at a tertiary care cancer center. J Am Acad Dermatol. 2025 Sep;93(3):797-799.

Loeb S, Keith SW, Gross L, Hartman RL, Beer TM, Brierley KL, Cheng HH, Couvillon A, Dicker AP, Friedman S, Gomella LG, Karsh L, Kelly WK, Lallas CD, Leader AE, Mann MJ, Mark JR, Mille P, Paller CJ, Rana HQ, Sokolova AO, Trabulsi EJ, Whang YE, and Giri VN. Patient-Reported Outcomes from Males Regarding Germline Testing For Prostate Cancer: Results from the PROGRESS Registry. JCO Precis Oncol. 2025 Sep;9:e2500571. doi: 10.1200/PO-25-00571. Epub 2025 Sep 19. PMID: 40971753; PMCID: PMC12462908.

Morrison LJ, Otis-Green S, Bruno J, Fordham PN, Carey EC. A Decade of Interactive Educational Exchange: Impacting Interprofessional Palliative Care Education. J Pain Symptom Manage. 2025 Sep 2:S0885-3924(25)00756-0.

Roessler N, Aneja S, An Y, Miszczyk M, Leapman MS. Association between prostate radiotherapy and survival among patients with metastatic prostate cancer by extent of disease burden. Radiother Oncol. 2025 Sep 21;213:111158.

Kim SY, Politi K, Goldberg SB. Lasering in on Uncommon EGFR Mutations. J Thorac Oncol. 2025 Sep;20(9):1148-1151.

Kidacki M, Cho C, Lopez-Giraldez F, Huang B, He J, Gaule P, Chen L, Vesely MD. PD-1H (VISTA) Expression in Cutaneous Squamous Cell Carcinoma Is Correlated with T-Cell Infiltration and Activation. J Invest Dermatol. 2025 Sep;145(9):2313-2324.e6.

Hamid SA, Moses J, Lynch OF, Washington R, Dicks M, Greenup RA, Proussaloglou EM. Financial Outlook thRough CAncer STorytelling (FOReCAST): Development of a Novel Video-Based Storytelling Intervention to Mitigate Financial Hardship Among Young Women with Breast Cancer. Ann Surg Oncol. 2025 Sep 24.

Huang W, Ma X, Clark M, Xu X. Diagnostic Evaluation for Abnormal Uterine Bleeding at Emergency Departments in the United States. Womens Health Issues. 2025 Sep-Oct;35(5):306-313.

Canavan ME, Cheng L, Xiang JJ, Lin JK, Hui D, Zhao H, Nortje N, Ratan R, Cherny N, Pham T, Giordano SH, Niu J, Adelson KB. Association Between Systemic Anticancer Therapy Administration Near the End of Life With Health Care and Hospice Utilization in Older Adults: A SEER Medicare Analysis of End-of-Life Care Quality. J Clin Oncol. 2025 Sep 26:JCO2500530.

Zhang JY, Rajendran BK, Desai SS, Gibson J, DiPalermo J, LoRusso P, Kong Y, Zhao H, Cecchini M, Schalper KA MD. High MGMT expression identifies aggressive colorectal cancer with distinct genomic features and immune evasion properties. J Immunother Cancer. 2025 Sep 10;13(9):e011653.

Lindsay ME, Clappier M, de Oliveira S, Gleeson D, Feifer D, O'Bryan SK, Kessler A, Mali N, Crabtree VM, Dean SM, Campbell PK, Snaman JM, Kaye EC, Ananth P. "A Double-Edged Sword": Influence of the 21st Century Cures Act on the Childhood, Adolescent, and Young Adult Cancer Care Experience. J Natl Compr Canc Netw. 2025 Sep 15:1-9. doi: 10.6004/jnccn.2025.7053. Epub ahead of print.

Baum LVM, Soulos PR, Kc M, Jeffery MM, Ruddy KJ, Lerro CC, Lee H, Graham DJ, Rivera DR, Liberatore M, Leapman MS, Jairam V, Dinan MA, Gross CP, Park HS. Opioid prescribing trends and pain scores among adult patients with cancer in a large health system. Cancer. 2025 Oct 1;131(19):e70027.

Xinyan Zhang, Qian Xiao, Longhui Zeng, Fawzaan Hashmi, Kazuki Sato, Tobias Max Philipp Hartwich, Miranda Mansolf, Yang Yang-Hartwich, Xiaolei Su. IDR-induced CAR condensation improves the cytotoxicity of CAR-Ts against low-antigen cancers. Nat Chem Biol (2025) 29 Sept.

Lin HK, Dai J, Pusztai L. Integrating large-scale in vitro functional genomic screen and multi-omics data to identify novel breast cancer targets. Breast Cancer Res Treat. 2025 Sep 1.

Ettorre VM, Demirkiran C, Bellone S, Hartwich TMP, Greenman M, McNamara B, Sethi N, Palmieri L, Santin AD. Effective preclinical activity of datopotamab deruxtecan (Dato-DXd), an ADC targeting trophoblast cell-surface antigen 2 (TROP2), against primary cervical carcinoma cell lines and xenografts. Gynecol Oncol. 2025 Sep 3;201:195-202.

Stoian A, Duru Ç, Chogan F, Biniazan F, Temple B, Karoubi G, Haykal S. Breast Tissue Reconstruction Strategies: A Tissue Engineering Approach. Tissue Eng Part B Rev. 2025 Sep 5.

Domínguez-Vigil IG, Banik K, Baro M, Contessa JN, Hayman TJ. PLK4 Inhibition as a Strategy to Enhance Non-Small Cell Lung Cancer Radiosensitivity. Mol Cancer Ther. 2025 Sep 2;24(9):1350-1361.

Santin NG, Sethi N, Bellone S, Demirkiran C, Ettorre VM, Greenman M, McNamara B, Buza N, Hartwich TMP, Palmieri L, Lorusso D, Santin AD. Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody-Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas. Cancer Res Commun. 2025 Sep 1;5(9):1611-1620.

Bhatia A, Mehra R, Bauman J, Khan SA, Wei W, Neumeister V, Sandoval-Schaefer T, Alpaugh RK, Lango M, Rimm DL, Ridge JA, Burtness B. Phase II Trial of Chemotherapy, Cetuximab, and Erlotinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck. Head Neck. 2025 Sep;47(9):2373-2382.

Zeng L, Zhang X, Xiong Y, Sato K, Hajicek N, Kogure Y, Kataoka K, Ogawa S, Sondek J, Su X. Hyperactive PLCG1 induces cell-autonomous and bystander T cell activation and drug resistance. EMBO Rep. 2025 Sep;26(18):4563-4586.

August

Al Mouslmani M, Alahmad MA, Akman Z, Rossi R, Rahman M, Nanna MG. CHA₂DS₂-VASc Score in Patients With Atrial Fibrillation and Cancer: A U.S. Nationwide Study. Am J Cardiol. 2025 Aug 15;249:59-64.

Liu M, Jin S, Agabiti SS, Jensen TB, Yang T, Radda JSD, Ruiz CF, Baldissera G, Rajaei M, Li FY, Townsend JP, Muzumdar MD, Wang S. Tracing the evolution of single-cell 3D genomes in Kras-driven cancers. Nat Genet.
2025 Aug 18

Nassar AH, Kim C, Adeyelu T, Bou Farhat E, Abushukair H, Rakaee M, Matteson K, Lau SF, Takabe Y, Ocejo A, Ardeshir-Larijani F, Leal T, Ramalingam S, Alam S, Gray JE, Hicks J, Kaldas D, Baena J, Berjaga MZ, Nana FA, Grohe C, Leuders H, Citarella F, Cortellini A, Mingo EC, Pancirer D, Das M, Ellis-Caleo TJ, Cheung JM, Lin JJ, Watson AS, Camidge DR, Sridhar A, Parikh K, Crowley F, Marron TU, Aggarwal V, Ahmed M, Sankar K, Kawtharany H, Zhang J, Owen DH, Li M, Nagasaka M, Pinato DJ, Awosika N, Alhamad K, Puri S, Zaman U, Gupta DM, Lau C, Khan H, Liauw J, Velazquez AI, Brown T, Moliner L, Mosteiro M, Rocha P, Evans M, Vanderwalde A, Elliott A, Nieva J, Lopes G, Ma PC, Borghaei H, Lee M, Young L, Aljumaily R, Mirza H, Kwiatkowski DJ, Herbst RS, Flavell RA, Naqash AR, Chiang AC. Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma. Nat Commun. 2025 Aug 19;16(1):7717.

Fang Z, Monteiro VS, Oh C, Janabi KA, Romero L, Ahsan N, Yang L, Peng L, DiMaio D, Lucas C, Chen S. A modular vaccine platform for optimized lipid nanoparticle mRNA immunogenicity. Nat Biomed Eng. 2025 Aug 25.

Mayday MY, Biancon G, Wei M, Ramirez C, Moratti I, Pintado-Urbanc AP, Espinosa JA, Chen M, Wang L, Simon MD, Ofir-Rosenfeld Y, Rausch O, Tebaldi T, Halene S, Krause DS. RBM15-MKL1 fusion protein promotes leukemia via m6A methylation and Wnt pathway activation. Blood. 2025 Aug 28;146(9):1096-1109.

Zeidan AM, Zhao R, Epstein RS, Salimi T. Oral decitabine and cedazuridine for the treatment of myelodysplastic syndromes: an integrated review of clinical, economic and patient-centered evidence. Expert Rev Anticancer Ther. 2025 Aug 9:1-8.

Dai Y, Aizenbud L, Qin K, Austin M, Jaycox JR, Cunningham J, Wang EY, Zhang L, Fischer S, Carroll SM, van Aggelen H, Kluger Y, Herold KC, Furchtgott L, Kluger HM, Ring AM. Humoral determinants of checkpoint immunotherapy. Nature. 2025 Aug;644(8076):527-536.

Yang X, Chen L. Why has immune "checkpoint" therapy failed in most clinical trials? J Immunother Cancer. 2025 Aug 27;13(8):e012457.

JULY

Herbst RS, Chen L. The evolving immuno-angiogenic paradigm in NSCLC: lessons from ivonescimab. Nat Rev Clin Oncol. 2025 Jul;22(7):461-462. doi: 10.1038/s41571-025-01024-y. PMID: 40329050.

Lin AC, Moscarelli J, Zhu YL, Lin ZP, Ratner ES. CXCL10-induced regulatory T cells and adenosine signaling promote immunosuppression and progression of epithelial ovarian cancer. Sci Rep. 2025 Jul 1;15(1):20778.

Jessica B Lewis, Ash Alpert, Deron Galusha, Alie Brussel Faria, Allister Hirschman, Hill L Wolfe, Lou Hart, Marcella Nunez-Smith, Karen H Wang, Patient perspectives on safety and privacy in sexual orientation and gender identity data collection, JNCI Monographs, Volume 2025, Issue 69, July 2025, Pages 170–176, https://doi.org/10.1093/jncimonographs/lgaf015

Costa PA, Hardy N, LoRusso P. PALB2 c.3106G>C (p.Val1036Leu) in a familial cancer setting suggesting potential pathogenicity. BMJ Case Rep. 2025 Jul 31;18(7):e266362.

Brown LM, Olino K. Non-Cutaneous Melanoma: Biology, Clinical Management, Current Therapy, and Future Directions in Treatment. Surg Oncol Clin N Am. 2025 Jul;34(3):453-471.

Mattia A, Hadzimustafic N, Rivero R, Oh SJ, Bach K, Brown S, Haykal S. Disparities in Breast Cancer-related Lymphedema: A Systematic Review of Inequities and Barriers in Care. Plast Reconstr Surg Glob Open. 2025 Jul 1;13(7):e6935.

Das S, Lenchner DS, Jaeger E, Hunihan L, DeSantis DF, Fragkogianni S, Ronski K, Wilson FH. Genetic and oncogenic features of RASGRF fusions. NPJ Precis Oncol. 2025 Jul 5;9(1):224.

Quijano E, Martinez-Saucedo D, Ianniello Z, Pinto-Medici N, Rackear M, Chen H, Lola-Pereira L, Liu Y, Hegan D, Shan X, Tseng R, Yugawa D, Chowdhury S, Khang M, Singh JP, Abdullah R, Azhir P, Kashima S, Woods WS, Gosstola N, Turner BC, Squinto S, Ludwig DL, Bindra RS, Robert ME, Braun DA, Perez Pinera P, Saltzman WM, Escobar-Hoyos LF, Glazer PM. Systemic administration of an RNA binding and cell-penetrating antibody targets therapeutic RNA to multiple mouse models of cancer. Sci Transl Med. 2025 Jul 16;17(807):eadk1868.

Robbins CJ, He M, Chan N, Khaimova R, Bates K, Trontzas IP, Scott L, Moutafi M, Coleman CB, Hill S, Liebler DC, Fulton R, Rimm DL. Quantitative Multiplex Immunofluorescence Assay for Trophoblast Cell-Surface Antigen 2 and Human Epidermal Growth Factor Receptor 2 Expression in Breast Cancer: Toward Guiding Patient Selection for Antibody-Drug Conjugate Therapies. JCO Precis Oncol. 2025 Jul;9:e2500128.

Labaki C, Saad E, Madsen KN, Hobeika C, Bi K, Alchoueiry M, Camp S, Hou Y, Bakouny Z, Matar S, El Ahmar N, Nyman J, Zhang L, Priolo C, Rout R, Daou M, Khabibullin D, Salem S, Schindler N, Saliby RM, Meli K, Wells JC, Pimenta E, Takemura K, Park J, Eid M, Semaan K, Fu J, Denize T, El Hajj Chehade R, Machaalani M, Nawfal R, Khatoun WD, Saleh M, El Masri J, Haddad NR, Xu W, McGregor BA, Hirsch MS, Xie W, Heng DYC, McDermott DF, Signoretti S, Van Allen EM, Shukla SA, Choueiri TK, Henske EP, Braun DA. Tumor-Intrinsic and Microenvironmental Determinants of Impaired Antitumor Immunity in Chromophobe Renal Cell Carcinoma. J Clin Oncol. 2025 Jul 2:JCO2500234.

Trontzas IP, He M, Wurtz A, Robbins CJ, Robinson N, Bates K, Liu M, Aung TN, Scott L, Chan N, Burela S, Schillo J, Liebler DC, Hill S, Morrison RD, Vathiotis I, Syrigos KN, Goldberg SB, Politi K, Rimm DL. Quantitative Protein Expression of Antibody-Drug Conjugate Targets in EGFR Mutated and Wild-type Non-Small Cell Lung Cancer. Clin Cancer Res. 2025 Jul 1;31(13):2767-2776.

Canavan ME, Westvold S, Csik V, Franks J, Rocque G, Gross CP, Adelson KB. The association between clinical trial participation, drug costs, and performance in the Oncology Care Model. J Natl Cancer Inst. 2025 Jul 1;117(7):1503-1505. doi: 10.1093/jnci/djaf008. PMID: 39842859.

Irwin, M. Extending Cancer Survival with Exercise — Time for Oncology to Act N Engl J Med July 2025: 2025;393:82-85 Vol 393 No 1

Godfrey EL, Mahoney F, Bansal VV, Su DG, Hanna DN, Lopez-Ramirez F, Baron E, Turaga KK, Benson AB, Cusack J, Winer JH, Gunderson CG, Misdraji J, Shah R, Magge DR, Solsky I, Eng C, Eng OS, Shergill A, Shen JP, Foote MB; Peritoneal Surface Malignancies Consortium Group. Consensus guideline for the management of patients with appendiceal tumors, part 1: Appendiceal tumors without peritoneal involvement. Cancer. 2025 Jul 1;131(13):e35867.

Richman IB, Gross CP. Increasing Colorectal Cancer Screening Participation-Why Negative Studies Can Still Move the Needle. JAMA Intern Med. 2025 Jul 1;185(7):796.

Turaga KK. Intraperitoneal paclitaxel for peritoneal metastases from gastric cancer in Western populations. Cancer. 2025 Jul 15;131(14):e35961.

Rybkin A, Bhatia A, Park HS. Redefining Systemic Therapy Timing in Nasopharyngeal Cancer-Before, During, or After Radiation. JAMA Oncol. 2025 Jul 24.

Sivanesan N, Diaz GM, Sprenkle PC. Tissue-based gene expression testing in localized prostate cancer. Curr Opin Urol. 2025 Jul 1;35(4):432-438.

Ajjawi I, Rios A, Wei W, Park TS, Lustberg MB. Clinical, sociodemographic, and facility-related determinants of immunotherapy use in metastatic triple-negative breast cancer. Breast Cancer Res Treat. 2025 Jul;212(2):299-308.

JUNE

Lakshmipathi J, Santha S, Li M, Qian Y, Roy SF, Luheshi N, Politi K, Bosenberg M, Eyles J, Muthusamy V. Intratumoral IL12 mRNA administration activates innate and adaptive pathways in checkpoint inhibitor-resistant tumors resulting in complete responses. Cancer Immunol Immunother. 2025 Jun 25;74(8):250.

Herbst RS, John T, Grohé C, Goldman JW, Kato T, Laktionov K, Bonanno L, Tiseo M, Majem M, Dómine M, Ahn MJ, Kowalski DM, Pérol M, Sriuranpong V, Özgüroğlu M, Bhetariya P, Markovets A, Rukazenkov Y, Muldoon C, Robichaux J, Hartmaier R, Tsuboi M, Wu YL. Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer. Nat Med. 2025 Jun;31(6):1958-1968.

Godfrey EL, Mahoney F, Bansal VV, Su DG, Hanna DN, Lopez-Ramirez F, Baron E, Turaga KK, Benson AB 3rd, Cusack J, Winer JH, Gunderson CG, Misdraji J, Shah R, Magge DR, Solsky I, Eng C, Eng OS, Shergill A, Shen JP, Foote MB; Peritoneal Surface Malignancies (PSM) Consortium Group. (Yale). Consensus Guideline for the Management of Patients with Appendiceal Tumors, Part 1: Appendiceal Tumors Without Peritoneal Involvement. Ann Surg Oncol. 2025 Jun 25. doi: 10.1245/s10434-025-17359-w. Epub ahead of print. PMID: 40560498.

Desai SS, Salahuddin S, Yusuf R, Ranjan K, Gu J, Osmani L, Lin YW, Mehta S, Talmon R, Kang I, Kluger Y, Zhao H, Schalper K, Emu B. The tumor microenvironment of non-small cell lung cancer impairs immune cell function in people with HIV. J Clin Invest. 2025 Jun 3;135(14):e177310.

Bewersdorf JP, Hasle V, Shallis RM, Thompson E, Lopes de Menezes D, Rose S, Boss I, Mendez L, Podoltsev N, Stahl M, Kewan T, Halene S, Haferlach T, Fox BA, Zeidan AM. Integrated Immune Landscape Analysis of RNA Splicing Factor-Mutant AML and Higher risk MDS Treated with Azacitidine ± Durvalumab. Ther Adv Hematol. 2025 Jun 21;16:20406207251347344.

Prior D, Yang J, Nuño MM, Shaikh F, Frazier AL, Pashankar F. Standard-Dose Versus High-Dose Cisplatin for Intermediate/Poor-Risk Extracranial Malignant Germ Cell Tumors: Re-Analysis of Pediatric Oncology Group 9049 and Children's Cancer Group 8882 Trial Using Updated MaGIC Risk Stratification. Pediatr Blood Cancer. 2025 Jun;72(6):e31665.

Zhan H, Antony VM, Tang H, Theriot J, Liang Y, Hui P, Krishnamurti U, DiGiovanna MP. PTEN inactivating mutations are associated with hormone receptor loss during breast cancer recurrence. Breast Cancer Res Treat. 2025 Jun;211(2):441-447.

Kim SY, Park HS, Chiang AC. Small Cell Lung Cancer: A Review. JAMA. 2025 Jun 3;333(21):1906-1917.

Mattia A, Alomari M, Hyjazie T, Devisetti N, Shen Y, Haykal S. Breast Reconstruction in De Novo Metastatic Breast Cancer: A Systematic Review. Plast Reconstr Surg Glob Open. 2025 Jun 2;13(6):e6810.

Banik K, Hayman TJ. Role of PLK4 inhibition in cancer therapy. Cancer Metastasis Rev. 2025 Jun 13;44(2):55.

Odzer N, Chehayeb RJ, Schellhorn SE, Lustberg M, Gross CP, Lee D, Foldi J. Patterns of adjuvant bone modifying agent use in patients with early-stage breast cancer in the United States. Breast Cancer Res. 2025 Jun 11;27(1):102.

Winer EP, Levit LA, Basch E, Chavez-MacGregor M, Dubois R, Eckhardt SG, Ellis LM, Hudis CA, Schrag D, Speers C, Wilky BA, Tibbits M, Spence R, Garrett-Mayer E. Promoting Reasonable Career Expectations and Maximizing Professional Fulfillment for Academic Oncologists: ASCO Recommendations for Academic Medical Centers. J Clin Oncol. 2025 Jun 10;43(17):2017-2023.

Sundar R, Nakayama I, Markar SR, Shitara K, van Laarhoven HWM, Janjigian YY, Smyth EC. Gastric cancer. Lancet. 2025 Jun 7;405(10494):2087-2102.

Lee V, Moore NS, Doyle J, Hicks D, Oh P, Bodofsky S, Hossain S, Patel AA, Aneja S, Homer R, Park HS. Prediction of Lymph Node Metastasis in Non-Small Cell Lung Carcinoma Using Primary Tumor Somatic Mutation Data. JCO Clin Cancer Inform. 2025 Jun;9:e2400303.

Ravani LV, Calomeni P, Vilbert M, Madeira T, Wang M, Deng D, Testa L, Colombo Bonadio R, Clifton K, Wander SA, Lustberg M. Efficacy of Subsequent Treatments After Disease Progression on CDK4/6 Inhibitors in Patients With Hormone Receptor-Positive Advanced Breast Cancer. JCO Oncol Pract. 2025 Jun;21(6):832-842.

Ettorre VM, AlAshqar A, Sethi N, Santin AD. Personalized Treatment in Ovarian Cancer: A Review of Disease Monitoring, Biomarker Expression, and Targeted Treatments for Advanced, Recurrent Ovarian Cancers. Cancers (Basel). 2025 May 30;17(11):1822.

Dai F, Yao S, Wang M, Zhu Y, Qiu X, Sun P, Qiu C, Yin J, Shen G, Sun J, Wang M, Wang Y, Yang Z, Sang J, Wang X, Sun F, Cai W, Zhang X, Lu H. Improving AI models for rare thyroid cancer subtype by text guided diffusion models. Nat Commun. 2025 May 13;16(1):4449.

H Zhan, N Chan, D Rimm. 270 Pathological Response to Herceptin-containing Neoadjuvant Therapy in HER2 IHC2+/ISH+ and IHC3+ Early-Stage Breast Cancers Laboratory Investigation, Volume 105, Issue 3, 102494.

Loeb S, Vadaparampil ST, Giri VN. Germline testing for prostate cancer: current state and opportunities for enhanced access. EBioMedicine. 2025 Jun;116:105705. doi: 10.1016/j.ebiom.2025.105705.

Smani S, Jalfon M, Sundaresan V, Lokeshwar SD, Nguyen J, Halstuch D, Khajir G, Cavallo JA, Sprenkle PC, Leapman MS, Kim IY. Inter-reader reliability and diagnostic accuracy of PI-RADS scoring between academic and community care networks: How wide is the gap? Urol Oncol. 2025 Jun;43(6):396.e1-396.e7.

Ettorre VM, Bellone S, Greenman M, McNamara B, Palmieri L, Sethi N, Demirkiran C, Papatla K, Kailasam A, Siegel ER, Ratner E, Santin AD. A phase 2 trial of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability (NCT02899793): Updated survival and response analyses. Gynecol Oncol. 2025 Jun;197:110-115.

Fucito LM, Baldassarri SR, Wu R, Gueorguieva R, Morean ME, Herbst RS, Krishnan-Sarin S, O'Malley SS. Effects of oral nicotine pouches on cigarette smoking behaviour and tobacco harm exposure: a randomised pilot trial in adults. Tob Control. 2025 Jun 23:tc-2024-059094.

Parsons K, Montalvo M, Fischbach N, Taylor M, Alfaro S, Lustberg M. The Impact and Safety of GLP-1 Agents and Breast Cancer. Cancer Med. 2025 Jun;14(12):e70932.

Zhan PL, Canavan ME, Bader JM, Boffa DJ, Resio BJ, Woodard GA. Prolonged Survival in Mesothelioma Patients Without Surgical Resection: A National Cancer Database Analysis. Ann Thorac Surg. 2025 Jun 28:S0003-4975(25)00565-X.

Khajir G, Webb LT, Lokeshwar SD, Diaz GM, Anderson T, Choksi AU, Zhao J, Leapman MS, Sprenkle PC, Renzulli JF. Diagnostic performance of high-resolution micro-ultrasound and conventional ultrasound in fusion biopsy for clinically significant prostate cancer detection. Urol Oncol. 2025 Jun;43(6):399.e1-399.e8.

Venkat A, Youlten SE, San Juan BP, Purcell CA, Gupta S, Amodio M, Neumann DP, Lock JG, Westacott AE, McCool CS, Burkhardt DB, Benz A, Mollbrink A, Lundeberg J, van Dijk D, Holst J, Goldstein LD, Kummerfeld S, Krishnaswamy S, Chaffer CL. AAnet resolves a continuum of spatially-localized cell states to unveil intratumoral heterogeneity. Cancer Discov. 2025 Jun 24.

MAY

Woodard GA, Grau-Sepulveda M, Onaitis MW, Udelsman BV, David EA, Jacobs JP, Kosinski AS, Blasberg JD, Boffa DJ. Lobectomy vs Sublobar Resection in The Society of Thoracic Surgeons Database: Importance of Patient Factors and Lymph Node Evaluation. Ann Thorac Surg. 2025 May;119(5):1071-1081.

Jeon JE, Chen KT, Madison R, Schrock AB, Sokol E, Levy MA, Rozenblit M, Huang RSP, Pusztai L. Genomic landscape and homologous recombination repair deficiency signature in stage I-III and de novo stage IV primary breast cancers. Oncologist. 2025 May 8;30(5):oyaf089.

Kwaah PA, Mensah SA, Agyemang EA, Kekrebesi JS, Katkov D, Carboo A, Appah G, Rashid HA, Kwan JM. Atrial fibrillation in breast cancer therapy: does tamoxifen confer a lower risk than aromatase inhibitors? Cardiooncology. 2025 May 31;11(1):51.

Bitting RL, McNair C, Wyatt AW, Vandekerkhove G, Choi T, Leader AE, Blanding-Godbolt J, Gross L, Hamade K, Halabi S, Giri VN. Factors Affecting Genomic Testing in Prostate Cancer: Results From the Decision-Making, Experience, and Confidence In Determining Genomic Evaluation (DECIDE) Survey. JCO Precis Oncol. 2025May;9:e2400821.

Allen CJ, Danea HM, Smieliauskas F, Edge S, Greenup RA. Bringing value to cancer research. Front Oncol. 2025 May 15;15:1580575.

Leader AE, Godbolt JB, Crumpler N, Gross L, Hartman R, Keith SW, Giri VN. Utilizing peer educators to increase genetic testing for prostate cancer among black males: results of a randomized controlled trial. Natl Med Assoc. Published online May 29, 2025.

Loeb S, Vadaparampil ST, Giri VN. Germline testing for prostate cancer: current state and opportunities for enhanced access. EBioMedicine. 2025 May 20;116:105705.

Ajjawi I, Rios A, Wei W, Park TS, Lustberg MB. Clinical, Sociodemographic, and Facility-Related Factors Influencing HER2-Targeted Therapy in Metastatic Hormone Receptor-Negative, HER2-Positive Breast Cancer. Cancers (Basel). 2025 May 6;17(9):1579.

Schnell PM, Kassem M, Miah A, Ramaswamy B, Williams N, Cherian M, Stover DG, Gatti-Mays ME, Pariser A, Wesolowski R, Sardesai S, Sudheendra PK, Ormiston K, Mezzanotte JN, Orchard TS, Lustberg M. Changes in Glucose level During Chemotherapy Treatment in Patients With Stage I-IV Breast Cancer. Clin Breast Cancer. 2025 May 27:S1526-8209(25)00161-2. doi: 10.1016/j.clbc.2025.05.021.

Lokeshwar SD, Choksi AU, Smani S, Kong V, Sundaresan V, Sutherland R, Brito J, Renzulli JF, Sprenkle PC, Leapman MS. Pathologic prostate cancer grade concordance among high-resolution micro-ultrasound, systematic transrectal ultrasound and MRI fusion biopsy. Urol Oncol. 2025 May;43(5):336.e13-336.e20.

Udelsman BV, Bedrosian CK, Kawaguchi ES, Ding L, Wallace WD, Rosenberg G, Harano T, Wightman S, Atay S, Kim AW, Woodard G. Living on the edge: Role of adjuvant therapy after resection of primary lung cancer within 2 millimeters of a T-stage cutoff. J Thorac Cardiovasc Surg. 2025 May;169(5):1338-1345.e15.

Chehayeb RJ, Odzer N, Albany RA, Ferrucci L, Sarpong D, Perez-Escamilla R, Lewis JB, Phipps AI, Meisner A, Pusztai L. Breastfeeding attributable fraction of triple negative breast cancer in the US. NPJ Breast Cancer. 2025 May 7;11(1):40. doi: 10.1038/s41523-025-00755-6. PMID: 40328734; PMCID: PMC12055980.

Han Y, Cai G. Intraoperative frozen section diagnosis of lung specimens: An updated review. Semin Diagn Pathol. 2025 May;42(3):150901.

Bidikian A, Bewersdorf JP, Kewan T, Podoltsev NA, Stahl M, Zeidan AM. Imetelstat in myeloid malignancies: current data and future directions. Expert Rev Anticancer Ther. 2025 May;25(5):517-528.

Alhajahjeh A, Stahl M, Kim TK, Kewan T, Stempel JM, Zeidan AM, Bewersdorf JP. Contemporary understanding of myeloid-derived suppressor cells in the acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) tumor microenvironment. Expert Rev Anticancer Ther. 2025 May;25(5):435-456.

Nomura M, Spitzer A, Johnson KC, Garofano L, Nehar-Belaid D, Galili Darnell N, Greenwald AC, Bussema L, Oh YT, Varn FS, D'Angelo F, Gritsch S, Anderson KJ, Migliozzi S, Gonzalez Castro LN, ChowdhFury T, Robine N, Reeves C, Park JB, Lipsa A, Hertel F, Golebiewska A, Niclou SP, Nusrat L, Kellet S, Das S, Moon HE, Paek SH, Bielle F, Laurenge A, Di Stefano AL, Mathon B, Picca A, Sanson M, Tanaka S, Saito N, Ashley DM, Keir ST, Ligon KL, Huse JT, Yung WKA, Lasorella A, Verhaak RGW, Iavarone A, Suvà ML, Tirosh I. The multilayered transcriptional architecture of glioblastoma ecosystems. Nat Genet. 2025 May 9.

Spitzer A, Johnson KC, Nomura M, Garofano L, Nehar-Belaid D, Darnell NG, Greenwald AC, Bussema L, Oh YT, Varn FS, D'Angelo F, Gritsch S, Anderson KJ, Migliozzi S, Gonzalez Castro LN, Chowdhury T, Robine N, Reeves C, Park JB, Lipsa A, Hertel F, Golebiewska A, Niclou SP, Nusrat L, Kellet S, Das S, Moon HE, Paek SH, Bielle F, Laurenge A, Di Stefano AL, Mathon B, Picca A, Sanson M, Tanaka S, Saito N, Ashley DM, Keir ST, Ligon KL, Huse JT, Yung WKA, Lasorella A, Iavarone A, Verhaak RGW, Tirosh I, Suvà ML. Deciphering the longitudinal trajectories of glioblastoma ecosystems by integrative single-cell genomics. Nat Genet. 2025 May 9.

Herbst RS, Chen L. The evolving immuno-angiogenic paradigm in NSCLC: lessons from ivonescimab. Nat Rev Clin Oncol. 2025 May 6.

Chen L. PD-L1 and the dawn of modern cancer immunotherapy. Nat Med. 2025 May 5.

Fereydooni S, Valdez C, Williams LC, Verma A, Judson B. Racial Disparities in Perioperative Outcomes for Patients With Head and Neck Cancer. Head Neck. 2025 May;47(5):1336-1344.

Jairam V, Lindsay ME, Soulos PR, Gross CP, Prsic EH, Baum LVM, Park HS. Temporal Trends in Opioid Use and Associated Outcomes for Patients Living with Advanced Cancer. J Pain Symptom Manage. 2025 Sep;70(3):230-238.e7. Epub online May 2025.

APRIL

Ito S, Xicola RM, Sra M, Potnis KC, Singh V, Gershkovich P, Stites E, Gibson J, Krumholz HM, Llor X, Goshua G. Cost-effectiveness of Lynch Syndrome Screening in Colorectal Cancer: Universal Germline vs Sequential Screening. Clin Gastroenterol Hepatol. 2025 Apr 30:S1542-3565(25)00326-X.

Gould Rothberg BE, Morris JC. Impact of skilled nursing facility discharge on inpatient oncology quality outcomes. JNCI Cancer Spectr. 2025 Apr 30;9(3):pkaf055. doi: 10.1093/jncics/pkaf055. PMID: 40408163; PMCID: PMC12202314.

Fish, A.G., Madoff, D.C. The Role of the Interventional Radiologist in Stopping Bleeding in Cancer Patients. Curr Oncol Rep 27, 483–489 (2025).

Francisco Exposito, Kelli A. Connolly, Tang Tang, Michael Chiorazzi, Brian G. Hunt, Jordan J. Cardenas, Don X. Nguyen, Nikhil S. Joshi, and Katerina Politi. Preclinical Models of Solid Cancers for Testing Cancer Immunotherapies. Annual Review of Cancer Biology. April 2025.

Dai J, Rozenblit M, Li X, Shan NL, Wang Y, Mane S, Marczyk M, Pusztai L. Genomic alterations in normal breast tissues preceding breast cancer diagnosis. Breast Cancer Res. 2025 Apr 22;27(1):60.

Huang S, Westvold SJ, Soulos PR, Fan J, Winer EP, Zhan H, Lustberg MB, Lewin J, Robinson TJ, Dinan MA. Screening History, Stage at Diagnosis, and Mortality in Screen-Detected Breast Cancer. JAMA Netw Open. 2025 Apr 1;8(4):e255322.

Wang X, Rothen J, Huang S, Long JB, Soulos PR, Goldberg SB, Mamtani R, Presley CJ, Kunst N, Ma S, Wang SY, Gross CP, Dinan MA. Adoption of Broad Genomic Profiling in Patients With Cancer. JAMA Oncol. 2025 Apr 17:e250499.

Do LK, Lee HM, Ha YS, Lee CH, Kim J. Amino acids in cancer: Understanding metabolic plasticity and divergence for better therapeutic approaches. Cell Rep. 2025 Apr 22;44(4):115529.

Lerner BA, Gupta S, Burke CA, Kupfer S, Katona BW, Grady WM, Samadder JJ, Yurgelun MB, Kelly KJ, Moreno Prats M, Joseph N, Idos GE, Swanson BJ, Kieber-Emmons A, Weiss JM, Llor X. Advancing the Evaluation and Management of CDH1-Associated Gastric Cancer. J Natl Compr Canc Netw. 2025 Apr;23(4):e257006.

Abdou Y, Kantor O, Racz J, Newman L, Pierce LJ, Winer EP. Prognostic and Predictive Insights From Genomic Assays for Breast Cancer in Diverse Populations: A Review. JAMA Oncol. 2025 Apr 3. Epub ahead of print.

Bhatia A, Mehra R, Bauman J, Khan SA, Wei W, Neumeister V, Sandoval-Schaefer T, Alpaugh RK, Lango M, Rimm DL, Ridge JA, Burtness B. Phase II Trial of Chemotherapy, Cetuximab, and Erlotinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck. Head Neck. 2025 Apr 1. Epub ahead of print.

Quandt Z, Perdigoto A, Anderson MS, Herold KC. Checkpoint Inhibitor-Induced Autoimmune Diabetes: An Autoinflammatory Disease. Cold Spring Harb Perspect Med. 2025 Apr 1;15(4):a041603.

Chiarella LS, Huelsboemer L, Diatta F, Klimitz FJ, Kammien AJ, Kochen A, Boroumand S, Allam O, Kauke-Navarro M, Pomahac B. ASO Author Reflections: The Five-Item Modified Frailty Index in Breast Cancer Surgery: Past Insights, Present Evidence, and Future Directions. Ann Surg Oncol. 2025 Apr 4. Epub ahead of print.

Robbins CJ, Bates KM, Rimm DL. HER2 testing: evolution and update for a companion diagnostic assay. Nat Rev Clin Oncol. 2025 Apr 7. Epub ahead of print.

Chiang AC, Olmedo Garcia ME, Carlisle JW, Dowlati A, Reguart N, Felip E, Jost PJ, Steeghs N, Stec R, Gadgeel SM, Loong HH, Jiang W, Hamidi A, Parkes A, Paz-Ares L. Safety of tarlatamab with 6-8-h outpatient versus 48-h inpatient monitoring during cycle 1: DeLLphi-300 phase 1 substudy. ESMO Open. 2025 Apr 4;10(4):104538. Epub ahead of print.

Knoedler S, Diatta F, Klimitz FJ, Noel O, Kempa J, Obed D, Song SY, Mayer H, Kim BS, Kauke-Navarro M, Pomahac B, Butler PD. Unveiling Inequities: Racial Disparities in Risk-Reducing Mastectomy for Breast Cancer Prevention. Clin Breast Cancer. 2025 Apr;25(3):e312-e320.

MARCH

Chiang AC, Madison RW, Assaf ZJ, Fine A, Cao Y, Gjoerup O, Huang Y, Jin DX, Hughes J, Antic V, Young A, Fabrizio D, Shames D, Maund S, Exarchos A, Lakhanpal S, Zuniga R, Pasquina LW, Schulze K. Real-World Validity of Tissue-Agnostic Circulating Tumor DNA Response Monitoring in Lung Cancers Treated With Chemotherapy, Immunotherapy, or Targeted Agents. JTO Clin Res Rep. 2025 Mar 19;6(9):100829.

Bellizzi KM, Emrich M, Park CL, Magin ZE, Gnall K, Sanft T. Trajectories of aerobic physical activity and fruit and vegetable intake in adults with cancer: Predictors and outcomes of class membership. J Cancer Surviv. 2025 Mar 29. Epub ahead of print.

Kim SY, Park HS, Chiang AC. Small Cell Lung Cancer: A Review. JAMA. 2025 Mar 31. Epub ahead of print.

Detterbeck FC, Kaminski HJ, Blasberg JD, O'Connor KC. Does thymectomy in adults have long-term health consequences? J Thorac Cardiovasc Surg. 2025 Mar;169(3):787-795.e2.

Caturegli G, Zhu X, Palis B, Mullett TW, Resio BJ, Boffa DJ. Smoking Status of the US Cancer Population and a New Perspective From the National Cancer Database. JAMA Oncol. 2025 Mar 27:e250247.

Norman KE, Buss MK, Lee KA, Escobar A, Thomas J, Berg J, Uwumugambi N, Dodge LE, Han HJ, Pilgrim C, Yeh JC. Impact of a Criteria-Based Inpatient Palliative Oncology Consultation Model on End-of-Life Outcomes. J Pain Symptom Manage. 2025 Mar;69(3):229-235.e1.

Arun AS, Liarakos D, Mendiratta G, Kim J, Goshua G, Olson P, Stites EC. Integrating epidemiology and genomics data to estimate the prevalence of acquired cysteine drug targets in the U.S. cancer patient population. Pharmacogenomics J. 2025 Mar 5;25(1-2):5.

Ranjan K, Rajendran BK, Deen IU, Costantini A, de Rodas ML, Desai SS, Scallo F, Gianino N, Ferrone S, Schalper KA. IL-4 mediated TAP2 downregulation is a dominant and reversible mechanism of immune evasion and immunotherapy resistance in non-small cell lung cancer. Mol Cancer. 2025 Mar 17;24(1):80.

Su X. CAR-T Entering a New "Phase": Improving CAR-T Function by Harnessing Phase Separation. Cancer Res. 2025 Mar 14;85(6):1011-1012.

Fish AG, Park HS, Knight E, Knowlton CA, Madoff DC. Percutaneous Cryoablation of Non-small Cell Lung Cancer in Patients with Recurrence After Stereotactic Body Radiation Therapy. Cardiovasc Intervent Radiol. 2025 Mar 11.

Zhan H, Antony VM, Tang H, Theriot J, Liang Y, Hui P, Krishnamurti U, DiGiovanna MP. PTEN inactivating mutations are associated with hormone receptor loss during breast cancer recurrence. Breast Cancer Res Treat. 2025 Mar 10.

Pusztai L, Hoag JR, Albain KS, Barlow WE, Stemmer SM, Meisner A, Hortobagyi GN, Shak S, Rae JM, Baehner R, Sharma P, Kalinsky KM. Development and Validation of the RSClinN+ Tool to Predict Prognosis and Chemotherapy Benefit for Hormone Receptor-Positive, Node-Positive Breast Cancer. J Clin Oncol. 2025 Mar 10;43(8):919-928.

Tang K, Zhou L, Tian X, Fang SY, Vandenbulcke E, Du A, Shen J, Cao H, Zhou J, Chen K, Kim HR, Luo Z, Xin S, Lin SH, Park D, Yang L, Zhang Y, Suzuki K, Majety M, Ling X, Lam SZ, Chow RD, Ren P, Tao B, Li K, Codina A, Dai X, Shang X, Bai S, Nottoli T, Levchenko A, Booth CJ, Liu C, Fan R, Dong MB, Zhou X, Chen S. Cas12a-knock-in mice for multiplexed genome editing, disease modelling and immune-cell engineering. Nat Biomed Eng. 2025 Mar 20.

Herbst RS, John T, Grohé C, Goldman JW, Kato T, Laktionov K, Bonanno L, Tiseo M, Majem M, Dómine M, Ahn MJ, Kowalski DM, Pérol M, Sriuranpong V, Özgüroğlu M, Bhetariya P, Markovets A, Rukazenkov Y, Muldoon C, Robichaux J, Hartmaier R, Tsuboi M, Wu YL. Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer. Nat Med. 2025 Mar 17.

Kuhn TN, Engelhardt WD, Kahl VH, Alkukhun A, Gross M, Iseke S, Onofrey J, Covey A, Camacho JC, Kawaguchi Y, Hasegawa K, Odisio BC, Vauthey JN, Antoch G, Chapiro J, Madoff DC. Artificial Intelligence-Driven Patient Selection for Preoperative Portal Vein Embolization for Patients with Colorectal Cancer Liver Metastases. J Vasc Interv Radiol. 2025 Mar;36(3):477-488.

Kimchi G, Lamsam L, Gu B, Mendel E, Harel R, Knoller N, Cohen ZR, Ungar L, Zibly Z. Minimally Invasive Anterolateral Cervical Cordotomy for Intractable Cancer Pain Using Microtubular Retractors: A Single Institution Case Series. Oper Neurosurg (Hagerstown). 2025 Mar 1;28(3):386-390.

Cannataro VL, Bracci PM, Taylor JW, McCoy L, Rice T, Hansen HM, Heffernan AE, Wiemels J, Wiencke J, Wrensch M, Claus EB. Glioma mutational signatures associated with haloalkane exposure are enriched in firefighters. Cancer. 2025 Mar 15;131(6):e35732.

Norman KE, Buss MK, Lee KA, Escobar A, Thomas J, Berg J, Uwumugambi N, Dodge LE, Han HJ, Pilgrim C, Yeh JC. Impact of a Criteria-Based Inpatient Palliative Oncology Consultation Model on End-of-Life Outcomes. J Pain Symptom Manage. 2025 Mar;69(3):229-235.e1.

Clark CJ, Wang R, Wiemels JL, Metayer C, Deziel NC, Ma X. Perinatal exposure to ambient fine particle air pollution and risk of childhood ewing sarcoma in a population-based case-control study in California (1988-2015). Environ Health. 2025 Mar 7;24(1):6.

Hamid SA, Lee DH, Herrin J, Yu JB, Pollack CE, Dean LT, Gaddy JJ, Oladele CR, Feder SL, Canavan ME, Nunez-Smith M, Soulos PR, Gross CP. Mediators of Racial Inequities in Non-Small Cell Lung Cancer Care. Cancer Med. 2025 Mar;14(5):e70757.

Lopez de Rodas M, Villalba-Esparza M, Sanmamed MF, Chen L, Rimm DL, Schalper KA. Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach. Nat Rev Clin Oncol. 2025 Mar;22(3):163-181.

Nassar AH, Abou Alaiwi S, El Zarif T, Denu R, Macaron W, Abdel-Wahab N, Freeman D, Vasbinder A, Hayeck S, Anderson E, Goodman RS, Johnson DB, Grynberg S, Shapira R, Kwan JM, Woodford R, Long GV, Haykal T, Dent S, Kojima Y, Yonemor K, Tandon A, Trevino A, Akhter N, Yang EH, Hui G, Drakaki A, El-Am E, Kozaily E, Al-Hader A, Bou Farhat E, Babu P, Mittra A, Li M, Jones N, Baena J, Juarez Herrera M, Foderaro S, Nana FA, Kim C, Sackstein P, Parikh K, Desai AP, Smith C, Cortellini A, Pinato DJ, Korolewicz J, Lopetegui-Lia N, Funchain P, Choudhary A, Asnani A, Navani V, Meyers D, Stukalin I, Ocejo Gallegos JA, Trent J, Nusrat S, Malvar C, McKay RR, Neilan TG, Choueiri TK, Naqash AR. Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study. J Immunother Cancer. 2025 Mar 3;13(3):e009364.

Belitzky E, Ravani Carvalho LV, Taylor M, Ortiz CN, Baum L, Fiellin DA, Lustberg MB. Psychedelics for Cancer Pain and Associated Psychological Distress: A Narrative Review of a Potential Strategy. Cancer Med. 2025 Mar;14(5):e70586.

Gaspar E, Yi I, Bar N. Once weekly bortezomib decreases rates of peripheral neuropathy without diminishing efficacy as compared to twice weekly bortezomib in combination with lenalidomide, dexamethasone and daratumumab, a single center retrospective analysis. Leuk Lymphoma. 2025 Mar 10:1-4.

Herbst RS, John T, Grohé C, Goldman JW, Kato T, Laktionov K, Bonanno L, Tiseo M, Majem M, Dómine M, Ahn MJ, Kowalski DM, Pérol M, Sriuranpong V, Özgüroğlu M, Bhetariya P, Markovets A, Rukazenkov Y, Muldoon C, Robichaux J, Hartmaier R, Tsuboi M, Wu YL. Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer. Nat Med. 2025 Mar 17.

FEBRUARY

Taddei, Tamar H.1,2; Brown, Daniel B.3; Yarchoan, Mark4; Mendiratta-Lala, Mishal5; Llovet, Josep M.6,7,8. Critical Update: AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology ():10.1097/HEP.0000000000001269, February 24, 2025.

Braun DA, Moranzoni G, Chea V, McGregor BA, Blass E, Tu CR, Vanasse AP, Forman C, Forman J, Afeyan AB, Schindler NR, Liu Y, Li S, Southard J, Chang SL, Hirsch MS, LeBoeuf NR, Olive O, Mehndiratta A, Greenslade H, Shetty K, Klaeger S, Sarkizova S, Pedersen CB, Mossanen M, Carulli I, Tarren A, Duke-Cohan J, Howard AA, Iorgulescu JB, Shim B, Simon JM, Signoretti S, Aster JC, Elagina L, Carr SA, Leshchiner I, Getz G, Gabriel S, Hacohen N, Olsen LR, Oliveira G, Neuberg DS, Livak KJ, Shukla SA, Fritsch EF, Wu CJ, Keskin DB, Ott PA, Choueiri TK. A neoantigen vaccine generates antitumour immunity in renal cell carcinoma. Nature. 2025 Feb 5.

Coppersmith NA, Schultz KS, Esposito AC, Cruickshank K, Saleh A, Linhares SM, Leeds IL, Pantel HJ, Reddy VB, Longo WE, Mongiu AK. Colorectal surgeon practice patterns of low anterior resection syndrome after rectal cancer treatment. Support Care Cancer. 2025 Feb 24;33(3):218.

Turan V, Bedoschi G, Lee DY, Barbosa CP, de Oliveira R, Sacinti KG, Sonmezer M, Lambertini M, Massarotti C, Schaub A, Wang E, Gayete-Lafuente S, Dunlop C, Anderson RA, Bang H, Oktay KH. Trends and Regional Differences for Fertility Preservation Procedures in Women With Breast Cancer. Clin Breast Cancer. 2025 Feb;25(2):108-116.e1.

Turocy T, Crawford JM. Bacterial small molecule metabolites implicated in gastrointestinal cancer development. Nat Rev Microbiol. 2025 Feb;23(2):106-121.

Experiences of Simulated Phone Death Notification. Murtha TD, Johnson RR, Ellman MS, Martin AS, Morrison LJ, Talwalkar JS.Clin Teach. 2025 Feb;22(1):e13846.

Prostate cancer in people with HIV. Sigel K, Yu R, Chiao E, Deshmukh A, Leapman MS. Curr Opin Infect Dis. 2025 Feb 1;38(1):10-17.

Wang M, Cai G, Gilani SM. TRPS1 expression in cytologic specimens of salivary duct carcinoma and other salivary gland tumors. Ann Diagn Pathol. 2025 Feb;74:152406.

Marczyk M, Kahn A, Silber A, Rosenblit M, Digiovanna MP, Lustberg M, Pusztai L. Trends in breast cancer-specific death by clinical stage at diagnoses between 2000 and 2017. J Natl Cancer Inst. 2025 Feb 1;117(2):287-295.

Cecchini M, Pilat MJ, Uboha N, Azad NS, Cho M, Davis EJ, Ahnert JR, Tinoco G, Shapiro GI, Khagi S, Powers B, Spencer K, Groisberg R, Drappatz J, Chen L, Das B, Bao X, Li J, Narayan A, Vu D, Patel A, Niger M, Doroshow D, Durecki D, Boerner SA, Bindra R, Ivy P, Shyr D, Shyr Y, LoRusso PM. Olaparib in treatment-refractory isocitrate dehydrogenase 1 (IDH1)- and IDH2-mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial. Cancer. 2025 Feb 15;131(4):e35755.

Robles JT, Stiegler AL, Boggon TJ, Turk BE. Cancer hotspot mutations rewire ERK2 specificity by selective exclusion of docking interactions. J Biol Chem. 2025 Feb 25:108348.

Ko CJ. Healing while healing: Navigating breast cancer as a doctor. J Am Acad Dermatol. 2025 Feb 21:S0190-9622(25)00326-3.

Cecchini M, Pilat MJ, Uboha N, Azad NS, Cho M, Davis EJ, Ahnert JR, Tinoco G, Shapiro GI, Khagi S, Powers B, Spencer K, Groisberg R, Drappatz J, Chen L, Das B, Bao X, Li J, Narayan A, Vu D, Patel A, Niger M, Doroshow D, Durecki D, Boerner SA, Bindra R, Ivy P, Shyr D, Shyr Y, LoRusso PM. Olaparib in treatment-refractory isocitrate dehydrogenase 1 (IDH1)- and IDH2-mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial. Cancer. 2025 Feb 15;131(4):e35755.

Turan V, Bedoschi G, Lee DY, Barbosa CP, de Oliveira R, Sacinti KG, Sonmezer M, Lambertini M, Massarotti C, Schaub A, Wang E, Gayete-Lafuente S, Dunlop C, Anderson RA, Bang H, Oktay KH. Trends and Regional Differences for Fertility Preservation Procedures in Women With Breast Cancer. Clin Breast Cancer. 2025 Feb;25(2):108-116.e1.

Exarchos A, Bourla AB, Kaur M, Schulze K, Maund S, Cao Y, Zhao Y, Williams EH, Gaffey SC, Zuniga R, Lakhanpal S, Antic V, Doral M, Sy J, Meropol NJ, Chiang AC. Real-world enrollment for a prospective clinico-genomic database using a pragmatic technology-enabled platform. Contemp Clin Trials Commun. 2025 Feb 4;44:101446.

JANUARY

Rodríguez YM, Koomson AA, Perry RJ. Breast cancer shares many epidemiological, lifestyle, and local hormonal and metabolic underpinnings with endometrial and ovarian cancer: a narrative review. Transl Breast Cancer Res. 2025 Jan 21;6:8.

Ayoade OF, Canavan ME, Zolfaghari EJ, Caturegli G, Kim SY, Boffa DJ. Recent Survival Gains in Stage IV NSCLC by Sociodemographic Strata. JTO Clin Res Rep. 2025 Jan 17;6(4):100798.

Butensky SD, Kerekes D, Bakkila BF, Billingsley KG, Ahuja N, Johnson CH, Khan SA. Quality of gastrointestinal surgical oncology care according to insurance status. J Gastrointest Surg. 2025 Mar;29(3):101961. Epub 2025 Jan 10.

Canavan ME, Westvold S, Csik V, Franks J, Rocque G, Gross CP, Adelson KB. The association between clinical trial participation, drug costs, and performance in the Oncology Care Model (OCM). J Natl Cancer Inst. 2025 Jan 22:djaf008.

Sundaresan VM, Smani S, Rajwa P, Renzulli J, Sprenkle PC, Kim IY, Leapman MS. Prostate-specific antigen screening for prostate cancer: Diagnostic performance, clinical thresholds, and strategies for refinement. Urol Oncol. 2025 Jan;43(1):41-48.

Kudo M, Ren Z, Guo Y, Han G, Lin H, Zheng J, Ogasawara S, Li H, Kim JH, Zhao H, Li CL, Madoff DC, Ghobrial RM, Kawaoka T, Gerolami R, Ikeda M, Kumada H, El-Khoueiry AB, Vogel A, Peng X, Mody K, Dutcus C, Dubrovsky L, Siegel AB, Finn RS, Llovet JM; LEAP investigators. Lenvatinib plus pembrolizumab plus transarterial chemoembolisation (TACE) versus dual placebo plus TACE for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a randomised, double-blind, phase 3 study. Lancet 2025 Jan 18;405(10474):203-215.

Ng M, Cerezo-Wallis D, Ng LG, Hidalgo A. Adaptations of neutrophils in cancer. Immunity. 2025 Jan 14;58(1):40-58.

Rios-Hoyo A, Xiong K, Dai J, Yau C, Marczyk M, Garcia-Milian R, Wolf DM, Huppert LA, Nanda R, Hirst GL, Cobain EF, van 't Veer LJ, Esserman LJ, Pusztai L. Hormone Receptor-Positive HER2-Negative/MammaPrint High-2 Breast Cancers Closely Resemble Triple-Negative Breast Cancers. Clin Cancer Res. 2025 Jan 17;31(2):403-413.

Ayoade OF, Canavan ME, De Santis WP, Zhan PL, Boffa DJ. Surgical and endoscopic management of clinical T1b esophageal cancer. J Thorac Cardiovasc Surg. 2025 Jan;169(1):279-288.e5.

Harrington K, Kitano S, Gambardella V, Parkes EE, Moreno I, Alonso G, Doi T, Berz D, Gutierrez ME, Fernandez N, Schmohl M, Barrueco J, LoRusso P. Open-label, phase Ia study of STING agonist BI 1703880 plus ezabenlimab for patients with advanced solid tumors. Future Oncol. 2025 Jan;21(2):195-200.

Lu BY, Lucca LE, Lewis W, Wang J, Nogueira CV, Heer S, Rayon-Estrada V, Axisa PP, Reeves SM, Buitrago-Pocasangre NC, Pham GH, Kojima ML, Wei W, Aizenbud L, Bacchiocchi A, Zhang L, Walewski JJ, Chiang V, Olino K, Clune J, Halaban R, Kluger Y, Coyle AJ, Kisielow J, Obermair FJ, Kluger HM, Hafler DA. Circulating tumor-reactive KIR+CD8+ T cells suppress anti-tumor immunity in patients with melanoma. Nat Immunol. 2025 Jan;26(1):82-91.

Khubchandani JA, Suttiratana SC, Washington R, White-Bracey D, Kc M, Silber A, Fayanju OM, Butler PD, Menon A, Greenup RA. Living Flat: Stories from Women of Color After Mastectomy. Ann Surg Oncol. 2025 Jan;32(1):104-114.

Junejo MH, Oyebanji OI, Wang B, Cappello C, Wait B, Farrow E, Nathan M, Bowring J, Cuming T. Early detection of anal squamous cell carcinoma with the use of high-resolution anoscopy. Clin Exp Dermatol. 2025 Jan 27;50(2):395-398.

Are C, Schissel M, Murthy S. Series on The Lancet Oncology Commission on Global Cancer Surgery-Action 1: Clinical Care and Access to Cancer Surgery. Ann Surg Oncol. 2025 Jan;32(1):42-46.

Rozenblit M, Qing T, Ye Y, Zhao H, Hofstatter E, Singh V, Reisenbichler E, Murray M, Pusztai L. Rare germline variants in cancer-relevant genes are associated with breast cancer risk in young women with high-risk family history. Breast Cancer Res Treat. 2025 Jan;209(1):21-26.

Wang Y, Zhang Y, Li W, Salovska B, Zhang J, Li T, Li H, Liu Y, Kaczmarek LK, Pusztai L, Klein DE. GABAA receptor π forms channels that stimulate ERK through a G-protein-dependent pathway. Mol Cell. 2025 Jan 2;85(1):166-176.e5.

Jiang Z, Bi F, Ge Z, Mansolf M, Hartwich TMP, Kolesnyk V, Yang K, Park W, Kim D, Grechukhina O, Hui P, Kim SW, Yang-Hartwich Y. SORL1-Mediated EGFR and FGFR4 Regulation Enhances Chemoresistance in Ovarian Cancer. Cancers (Basel). 2025 Jan 13;17(2):244.

AACR Cancer Progress Report 2024 Steering Committee. New Approvals Advancing Blood Cancer Medicine. Blood Cancer Discov. 2025 Jan 8;6(1):5-9.

Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer with 34+ contributing authors including DiGiovanna, M. of Yale. 15 Jan 2025 N Engl J Med 2025;392:249-257

Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignancies. Bewersdorf JP, Mi X, Lu B, Kuykendall A, Sallman D, Patel M, Stevens D, Philipovskiy A, Sutamtewagul G, Masarova L, Keiffer G, Verma A, Bhagwat N, Wang M, Moore A, Rager J, Heiser D, Ro S, Hong WJ, Abdel-Wahab O, Stein EM. Leukemia. 2025 Jan 24.

Comparison of incident breast cancer cases in the largest national US tumor registries. Plichta JK, Thomas SM, Chanenchuk TC, Chan K, Hyslop T, Hwang ES, Greenup RA. Cancer. 2025 Jan 1;131(1):e35525. Online ahead of print

Prostate-specific antigen screening for prostate cancer: Diagnostic performance, clinical thresholds, and strategies for refinement. Sundaresan VM, Smani S, Rajwa P, Renzulli J, Sprenkle PC, Kim IY, Leapman MS Urol Oncol. 2025 Jan;43(1):41-48. doi: 10.1016/j.urolonc.2024.06.003.

Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline. #10; Click to follow link.">Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline. Yu EY, Rumble RB, Agarwal N, Cheng HH, Eggener SE, Bitting RL, Beltran H, Giri VN, Spratt D, Mahal B, Lu K, Crispino T, Trabulsi EJ. J Clin Oncol. 2025 Jan 9:JCO2402608.

Immunogenomic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma. Jammihal T, Saliby RM, Labaki C, Soulati H, Gallegos J, Peris A, McCurry D, Yu C, Shah V, Poduval D, El Zarif T, El Ahmar N, Laimon YN, Eid M, Sheshdeh AB, Krajewski KM, Büttner FA, Schwab M, Heng D, Casellas RC, Rai K, Zacharias Millward NM, Msaouel P, Karam J, Signoretti S, Van Allen E, Choueiri TK, Braun DA, Shukla SA. Nat Cancer. 2025 Jan 9.

DNA methylation in mammalian development and disease. Smith ZD, Hetzel S, Meissner A. Nat Rev Genet. 2025 Jan;26(1):7-30.

Varying the intensity of cystoscopic surveillance for high-risk non-muscle-invasive bladder cancer. Su ZT, Florissi IS, Mahon KM, Li T, Rezaee ME, Singla N, Patel SH, Townsend JP, Kates MR. BJU Int. 2025 Jan;135(1):148-155.

AAHPM Assessment Workgroup: Hospice and Palliative Medicine Fellowship Assessment Needs and Directions. Ketterer B, Dingfield L, Stowers KH, Morrison K, Bailey A, Flint H, Buckholz G, Morrison LJ, Yang H, Berns S. J Pain Symptom Manage. 2024 Dec 19:S0885-3924(24)01210-7.

Tumor-Specific Antigen Delivery for T-cell Therapy via a pH-Sensitive Peptide Conjugate. Yurkevicz AM, Liu Y, Katz SG, Glazer PM. Mol Cancer Ther. 2025 Jan 2;24(1):105-117.

Sorafenib or anthracycline-based chemotherapy for progressive desmoid tumors. Costa PA, Arora A, Fernandez Y, Yi I, Bakkila B, Tan H, Barreto Coelho P, Campoverde L, Hardy N, Bialick S, Espejo Freire A, D'Amato GZ, Chang YC, Mesenger JP, Subhawong T, Haims A, Hurwitz M, Olino K, Turaga K, Deshpande H, Trent J. Cancer. 2025 Jan 1;131(1):e35647.